Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective
Vaccine marketing authorization holders (MAHs) are responsible for the conduction of global vaccine pharmacovigilance on their vaccine products. A safety signal is detected when a new adverse event (AE) or aspect of an AE occurs after exposure to the vaccine and warrants further investigation to det...
Saved in:
| Main Authors: | Maria Maddalena Lino, Susan Mather, Marianna Trani, Yan Chen, Patrick Caubel, Barbara De Bernardi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/5/481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemic
by: Florence van Hunsel, et al.
Published: (2025-08-01) -
Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database
by: Xu Y, et al.
Published: (2025-05-01) -
SIGNAL AS A TOOL OF THE PHARMACOVIGILANCE
by: E. O. Zhuravleva, et al.
Published: (2018-06-01) -
Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01) -
Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database
by: Yating An, et al.
Published: (2025-07-01)